Ipsen Articles
Ipsen's nine-month sales increase 7%
10 November 2008
Circassia acquires rights to dopexamine from Ipsen
13 October 2008
Ipsen updates on Dysport progress at FDA
6 October 2008
Ipsen files for EU approval of six-month Decapeptyl
29 September 2008
Liraglutide improves multiple endpoints in LEAD-4
15 September 2008
Ipsen's first-half 2008 profit jumps 42%
8 September 2008
UPDATE: FDA considering strong warning on Byetta; potential fall-out for all GLP-1s
1 September 2008
Ipsen's first-half sales beat expectations
11 August 2008
Stock Commentary - Europe - week to July7, 2008
14 July 2008
Ipsen finalizes purchase of Vernalis
7 July 2008
Japan stock market week to June 23, 2008
30 June 2008
Roche's new diabetes drug goes into Ph III
16 June 2008
SJG-136 achieves partial response in OC patient
9 June 2008
Ipsen appoints VP global regulatory affairs
2 June 2008
FDA accepts Reloxin BLA, Ipsen gets $25M
26 May 2008
Ipsen reports 8.4% sales growth in 1st qtr
12 May 2008
Dominique Bridon joins Ipsen as VP, discovery
7 April 2008
Ipsen recruits Frederic Babin as Exec VP, HR
24 March 2008
Ipsen/Medicis submit Reloxin BLA to FDA
24 March 2008
Ipsen's 2007 operating profit climbs 12%
10 March 2008
GTx/Ipsen's toremifene meets key endpoints
3 March 2008
Ipsen's Adenuric gets nod from CHMP
3 March 2008
Six-month Decapeptyl similar to present forms
18 February 2008
US FDA opens safety review on Botox
18 February 2008
Ipsen's full-year 2007 sales beat expectations
11 February 2008
Delay to US NDA for Ipsen/Medicis' Reloxin
11 February 2008
Roche pipeline includes several potential blockbusters likely to enter Ph III testing
11 February 2008
Ipsen abandons EU NutropinAq application
4 February 2008
Ipsen and Salk enter alliance
21 January 2008
Ipsen and Galderma to co-develop Reloxin in Europe
10 December 2007
Ipsen and Medicis submit US BLA for Reloxin
10 December 2007
Ipsen filed BSA for Dysport with FDA
10 December 2007
Celera and Ipsen collaborate
26 November 2007
Ipsen's 9-month sales rise 5.5% to $994.5M
12 November 2007
Ipsen and Debiopharm extend Decapeptyl accord
5 November 2007
Stock Commentary - Europe - week to September 24, 2007
27 September 2007
Ipsen and bioMerieux sign theragnostics deal
24 September 2007
Japan stock market week to September 3, 2007
10 September 2007
Ipsen's Somatuline Depot cleared in USA
10 September 2007
Teijin and Chugai to develop Ipsen drug for Japan
10 September 2007
Ipsen's six-month net income drops 10%
3 September 2007
Ipsen/Tercica's Increlex approved in Europe
20 August 2007
Ipsen's 2nd-qtr 2007 sales up 8.1%
13 August 2007
Ipsen and PregLem sign licensing deal
2 July 2007
Disappointing Ph III triptorelin data
18 June 2007
Ipsen to invest 55M euros in Dreux by 2011
11 June 2007
Pres-elect Sarkozy lifts pharma hopes in France
14 May 2007
Ipsen's 1st-qtr 2007 sales rise 7% to $307M
14 May 2007
Ipsen names Sean McKercher VP US development
23 April 2007
Tanakan may still make reimbursement list
2 April 2007
Presidential campaign trail for France's G5
2 April 2007
Ipsen's FY 2006 sales rise 6.8% to $1.15B
26 March 2007
Ipsen and Galderma in botulinum toxin deal
5 March 2007
Ipsen's 2006 sales grow 6.8% to 861.7M euros
12 February 2007
Ipsen licenses MSD's Adrovance in France
5 February 2007
Ipsen acquires acromegaly regimen patent
29 January 2007
French drugmakers' growth declining
22 December 2006
Ipsen initiates Ph III trial of Decapeptyl SR
22 December 2006
Somatuline Autogel NDA submitted to FDA
13 November 2006
Ipsen nine-months sales up 8.8%
6 November 2006
EMEA validates Ipsen's febuxostat marketing application
9 October 2006
Ipsen licenses GTx' SERM Acapodene in EU
18 September 2006
Ipsen's 1st-half 2006 profit falls 6.6%
18 September 2006
Ipsen's 1st-half 2006 sales rise 7% to $550M
7 August 2006
Ipsen to move into USA via Tercica
31 July 2006
Ipsen and Increlex enter global endocrinology accord
24 July 2006
Roche licenses Ipsen's developmental antidiabetic
24 July 2006
Ipsen extends deadline for Medicis deal
24 April 2006
Ipsen fares well since Bourse listing
27 March 2006
Ipsen grants US botox rights to Medicis for $194M
27 March 2006
Ipsen licenses Reloxin to Medicis
20 March 2006
Drug prices lowered in French measures
13 February 2006
Ipsen sees 7.4% sales growth in 2005
13 February 2006
Pharma/biotech mergers and acquisitions during 2005
6 February 2006
Ipsen licenses BA058 to Radius
19 December 2005
Ipsen IPO raises $381 M
12 December 2005
Pierre Fabre valued at 1.02 billion euros
12 December 2005
Ipsen's Somatuline Autogel gets easier dosing regime in Portugal
19 September 2005
CORRECTION: Ipsen R&D
6 June 2005
France's Ipsen sees 8.6% sales growth
16 May 2005
French govt/pharma council: second meeting
9 May 2005
Genentech and Ipsen add to existing accord
28 March 2005
Highlights of pharmaceutical mergers and acquisitions in 2004
24 January 2005
French independents call for R&D funding
17 January 2005
France: reimbursement cut on vasodilators
20 December 2004
Auxilium/Ipsen's Testim OKed in EU
20 December 2004
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
